Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG.

Mefloquine is a quinoline antimalarial drug that is structurally related to the antiarrhythmic agent quinidine. Mefloquine is widely used in both the treatment and prophylaxis of Plasmodium falciparum malaria. Mefloquine can prolong cardiac repolarization, especially when coadministered with halofantrine, an antagonist of the human ether-a-go-go-related gene (HERG) cardiac K+ channel. For these reasons we examined the effects of mefloquine on the slow delayed rectifier K+ channel (KvQT1/minK) and HERG, the K+ channels that underlie the slow (I(Ks)) and rapid (I(Kr)) components of repolarization in the human myocardium, respectively. Using patch-clamp electrophysiology we found that mefloquine inhibited KvLQT1/minK channel currents with an IC50 value of approximately 1 microM. Mefloquine slowed the activation rate of KvLQT1/minK and more block was evident at lower membrane potentials compared with higher ones. When channels were held in the closed state during drug application, block was immediate and complete with the first depolarizing step. HERG channel currents were about 6-fold less sensitive to block by mefloquine (IC50 = 5.6 microM). Block of HERG displayed a positive voltage dependence with maximal inhibition obtained at more depolarized potentials. In contrast to structurally related drugs such as quinidine, mefloquine is a more effective antagonist of KvLQT1/minK compared with HERG. Block of KvLQT1/minK by mefloquine may involve an interaction with the closed state of the channel. Inhibition by mefloquine of KvLQT1/minK in the human heart may in part explain the synergistic prolongation of QT interval observed when this drug is coadministered with the HERG antagonist halofantrine.

[1]  D. Rampe,et al.  The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. , 1998, The Journal of pharmacology and experimental therapeutics.

[2]  K. Murray,et al.  Stereoselective interactions of the enantiomers of chromanol 293B with human voltage-gated potassium channels. , 2000, The Journal of pharmacology and experimental therapeutics.

[3]  N. White,et al.  A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. , 1993, British journal of clinical pharmacology.

[4]  G. Billman,et al.  Antiarrhythmic efficacy of selective blockade of the cardiac slowly activating delayed rectifier current, I(Ks), in canine models of malignant ischemic ventricular arrhythmia. , 1999, Circulation.

[5]  C. January,et al.  Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. , 1997, The American journal of physiology.

[6]  N. White,et al.  Clinical Pharmacokinetics of Mefloquine , 1990, Clinical pharmacokinetics.

[7]  P. Bennett,et al.  Modulation of HERG potassium channels by extracellular magnesium and quinidine. , 1999, Journal of cardiovascular pharmacology.

[8]  J. Papp,et al.  Pharmacological block of the slow component of the outward delayed rectifier current (IKs) fails to lengthen rabbit ventricular muscle QTc and action potential duration , 2001, British journal of pharmacology.

[9]  M. Keating,et al.  MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.

[10]  G. Edwards,et al.  Potentiation of halofantrine‐induced QTc prolongation by mefloquine: correlation with blood concentrations of halofantrine , 2001, British journal of pharmacology.

[11]  E. Green,et al.  A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.

[12]  G. Lefèvre,et al.  Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers , 2000, European Journal of Clinical Pharmacology.

[13]  P. Rosenthal,et al.  Drug overdoses with antimalarial agents: prescribing and dispensing errors. , 1998, Journal of the American Medical Association (JAMA).

[14]  A. Brown,et al.  A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG , 1997, FEBS letters.

[15]  F. Ajayi,et al.  ECG pharmacodynamics and pharmacokinetics of halofantrine and mefloquine , 1996 .

[16]  S Nattel,et al.  Effects of the chromanol 293B, a selective blocker of the slow, component of the delayed rectifier K+ current, on repolarization in human and guinea pig ventricular myocytes. , 1998, Cardiovascular research.

[17]  D. Roden,et al.  Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone. , 1991, Circulation research.

[18]  P. Coumel,et al.  A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome , 1997, Nature Genetics.

[19]  A. Brown,et al.  HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. , 1996, Circulation.

[20]  D. Rampe,et al.  High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide. , 2000, European journal of pharmacology.

[21]  Jacques Barhanin,et al.  KvLQT1 and IsK (minK) proteins associate to form the IKS cardiac potassium current , 1996, Nature.

[22]  R. Hauer,et al.  Genetic and Molecular Basis of Cardiac Arrhythmias: Impact on Clinical Management , 2022 .

[23]  J. Kopferschmitt,et al.  Clinical Features and Management of Poisoning due to Antimalarial Drugs , 1987, Medical toxicology and adverse drug experience.

[24]  R. N. Brogden,et al.  Mefloquine , 1993, Drugs.

[25]  D. Kyle,et al.  Cardiac effects of antimalarial treatment with halofantrine , 1993, The Lancet.

[26]  C. January,et al.  Block of HERG Potassium Channels by the Antihistamine Astemizole and its Metabolites Desmethylastemizole and Norastemizole , 1999, Journal of cardiovascular electrophysiology.

[27]  P. Waller,et al.  Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. , 1997, British Journal of Clinical Pharmacology.

[28]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[29]  M. Sanguinetti,et al.  Coassembly of KVLQT1 and minK (IsK) proteins to form cardiac IKS potassium channel , 1996, Nature.